港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

661.647

+7.4121.13%

涨家数：19

跌家数：14

平家数：1

市盈率：- -

高：666.959

开：654.173

低：636.061

收：654.235

成交量：9,431.67万

成交额：30.85亿

市值：4,212.01亿

流通市值：3,756.38亿

数据加载中...

总览新闻资讯

康宁杰瑞制药-B(09966)授出合共 25万股奖励股份

智通财经网

亿腾嘉和(06998)4月23日斥资340.08万港元回购100万股

归创通桥(02190)4月23日斥资113.17万港元回购5万股

诺诚健华：2026年一季度盈利1亿元

南方财经网

东阳光药(06887)：三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局

罗氏CEO感叹瑞郎走强，这家制药企业加大对美投资力度

环球市场播报

安徽万邦医药|深耕20载赋能创新药-以专业铸壁垒，以初心赴新程

再鼎医药(09688.HK)：5月7日董事会审议及批准第一季度业绩

汇伦医药三闯资本市场：业绩连亏两年，核心产品收入腰斩，估值增长近乎停滞

关注2026 ASCO：中国学者的研究项目入选数量再创新高，国产创新药有三大看点

每日经济新闻

汇率逆风撞上关键药物销售额失色罗氏卡在专利悬崖与创新药接力的十字路口

港股异动 | 创新药概念全线走低油价上涨压制降息空间市场关注创新药投融资前景

生物医药板块承压康方生物(09926)跌超10%、再鼎医药(09688)跌近7%

康方生物(09926)出现大手卖出11.6万股，成交价$132.0，涉资1.531千万

阿斯达克财经

港股异动 | 亿腾嘉和(06998)涨近4% 于2026年AACR年会公布四特异性抗体EDP001临床前研究数据

和誉-B(02256)：和誉医药于2026年AACR年会展示六项研究进展，聚焦pan-KRAS、四代EGFR及合成致死等创新路线

创胜集团医药-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER阳性╱HER2阴性乳腺癌PDX模型中显示出强大的抗肿瘤活性的新数据

恒瑞医药一季度创新药销售收入超45亿元；甘李药业募投项目延期｜医药早参

每日经济新闻

加科思-B(01167)4月22日耗资约49.12万港元回购6.27万股

艾伯维斥资14亿美元在北卡罗来纳州建制药园区

环球市场播报

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":661.64685,"timestamp":1777018105801,"preClose":654.2346,"halted":0,"volume":94316735,"delay":0,"changeRate":0.01133,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":7.412231,"latestTime":"04-24 16:00:00","open":654.17346,"high":666.9594,"low":636.06134,"amount":3085297395,"amplitude":0.047228,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776994200000,1777003200000],[1777006800000,1777017600000]],"pbRate":5.188237,"peRate":-88.006625,"turnoverRate":0.00339,"increases":18,"decrements":14,"flats":1,"marketCap":421200541216,"floatMarketCap":375638141760},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":666.9594,"amplitude":0.047228,"preClose":654.2346,"low":636.06134,"pbRate":"5.188237","latestPrice":661.64685,"volume":94316735,"delay":0,"open":654.17346,"prevYearClose":556.26263,"prevWeekClose":661.647,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":719.918,"twentyDayClose":567.335,"sixtyDayClose":569.48,"secType":"PLATE","market":"HK","turnoverRate":0.00339,"peRate":-88.006625,"marketCap":421200541216,"floatMarketCap":375638141760,"timestamp":1777018105801,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":19,"down":14,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629858434","title":"康宁杰瑞制药-B(09966)授出合共 25万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629858434","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629858434?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 22:27","pubTimestamp":1776954447,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年4月23日(授出日期)，根据限制性股份奖励计划，本公司决议向两名合资格参与者(奖励承授人)(彼等为本集团雇员)授出合共 25万股奖励股份(奖励股份)，以认购最多合共25万股每股面值0.000002 美元的本公司普通股(股份)，惟须待奖励承授人接纳后方可作实。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629090837","title":"亿腾嘉和(06998)4月23日斥资340.08万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629090837","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629090837?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 21:40","pubTimestamp":1776951628,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年4月23日该公司斥资340.08万港元回购100万股，回购价格为每股3.30-3.46港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亿腾嘉和(06998)4月23日斥资340.08万港元回购100万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","06998","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629716835","title":"归创通桥(02190)4月23日斥资113.17万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629716835","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629716835?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 19:31","pubTimestamp":1776943906,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2026年4月23日斥资113.17万港元回购5万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02190","BK1587","BK1574","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629780833","title":"诺诚健华：2026年一季度盈利1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629780833","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629780833?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 18:51","pubTimestamp":1776941460,"startTime":"0","endTime":"0","summary":"南方财经4月23日电，生物医药企业诺诚健华（09969.HK/688428.SH）披露2026年一季报，2026年第一季度药品收入同比增长44.5%至4.5亿元，由于药品收入的持续上涨以及全球商务拓展（BD），公司2026年第一季度总收入同比增长38.7%至5.3亿元，同期净利润1.0亿元。在此之前，公司于2025年首次实现年度盈利，归母净利润6.42亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716270246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1574","09969","BK1161","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880358","title":"东阳光药(06887)：三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629880358?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 18:25","pubTimestamp":1776939928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，于2026年4月17日至22日在美国加利福尼亚州圣地亚哥举行的 2026年美国癌症研究协会年会上，本集团以三份壁报形式集中展示了肿瘤治疗领域三款在研管线的最新临床前研究成果。上述三款创新药物在AACR年会上的集中亮相，不仅丰富了本集团的差异化产品管线，更展现了本集团在攻克不可成药靶点及开发下一代免疫疗法方面的技术积累与战略决心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","06887","159992","BK1191","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629881227","title":"罗氏CEO感叹瑞郎走强，这家制药企业加大对美投资力度","url":"https://stock-news.laohu8.com/highlight/detail?id=2629881227","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629881227?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 17:26","pubTimestamp":1776936360,"startTime":"0","endTime":"0","summary":"罗氏一季度销售额下滑 5%，但按固定汇率计算增长 6%。瑞郎兑多数货币升值，对该制药企业以瑞郎计价的业绩造成显著影响。首席执行官托马斯施内克为公司季度业绩辩护，对美国消费者新闻与商业频道表示，这 “只是看待财报口径的问题”，以美元计价的销售额增长了 9%。　　受瑞郎走强以及部分老牌药品面临仿制药竞争的影响，罗氏今年前三个月销售额出现下滑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-23/doc-inhvntfa5379431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","MSFmain","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629881865","title":"安徽万邦医药|深耕20载赋能创新药-以专业铸壁垒，以初心赴新程","url":"https://stock-news.laohu8.com/highlight/detail?id=2629881865","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629881865?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 17:06","pubTimestamp":1776935164,"startTime":"0","endTime":"0","summary":"医药创新，是守护生命健康的核心引擎，更是中国医药产业高质量发展的必由之路。在这条充满机遇与挑战的赛道上，安徽万邦医药科技股份有限公司深耕20载，从合肥高新区的初创团队，成长为安徽省CRO第一股、国家级专精特新“小巨人”，以临床CRO+生物分析为核心，成为国内医药创新产业链中不可忽视的服务力量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260423/32168027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","159992","BK0216","301520","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629688951","title":"再鼎医药(09688.HK)：5月7日董事会审议及批准第一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2629688951","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629688951?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 16:47","pubTimestamp":1776934021,"startTime":"0","endTime":"0","summary":"格隆汇4月23日丨再鼎医药公布，董事会审核委员会将于2026年5月7日(星期四)审议及批准根据美国公认会计准则及美国证券交易委员会的适用规则编制的公司及其附属公司截至2026年3月31日止三个月的未经审核季度业绩及其发布。　　在第一季度业绩获批准及发布后，公司管理层计划在2026年5月7日上午8:00/2026年5月7日下午8:00举行现场业绩电话会议及网络直播，以讨论第一季度业绩并回答提问。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260423/32167897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4526","LU2488822045.USD","BK4588","BK4585","ZLAB","BK4139","09688","BK4531","BK4548","BK1588","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629380886","title":"汇伦医药三闯资本市场：业绩连亏两年，核心产品收入腰斩，估值增长近乎停滞","url":"https://stock-news.laohu8.com/highlight/detail?id=2629380886","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629380886?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 16:24","pubTimestamp":1776932640,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2026年4月，上海汇伦医药股份有限公司正式向港交所递交招股书，开启其港股上市之旅，中信证券担任独家保荐人。这是汇伦医药在A股上市计划折戟、被新天药业收购计划终止后的第三次资本化尝试。　　招股书数据显示，公司2023年至2025年营收从9.85亿元骤降至6.86亿元，净利润由2065.9万元的盈利转为连续两年亏损，2025年亏损额进一步扩大至1.74亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-04-23/doc-inhvnnwy5017322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1515","09939","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629788831","title":"关注2026 ASCO：中国学者的研究项目入选数量再创新高，国产创新药有三大看点","url":"https://stock-news.laohu8.com/highlight/detail?id=2629788831","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629788831?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 15:05","pubTimestamp":1776927900,"startTime":"0","endTime":"0","summary":"　　从已公布的研究摘要来看，康方生物主导的HARMONi-6研究入选全体大会，这是中国研究第再次入选发布平台；此外，科伦博泰和默沙东将披露ADC+PD-1关键III期临床研究数据，这两项研究可能成为接下来5年引领非小细胞肺癌的核心疗法。此外，百利天恒自主研发的iza-bren一项三阴性乳腺癌研究入选LBA，也是本次大会亮点之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-04-23/doc-inhvnnxa8642537.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-23/doc-inhvnnxa8642537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629034000","title":"汇率逆风撞上关键药物销售额失色 罗氏卡在专利悬崖与创新药接力的十字路口","url":"https://stock-news.laohu8.com/highlight/detail?id=2629034000","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629034000?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 14:59","pubTimestamp":1776927545,"startTime":"0","endTime":"0","summary":"按固定汇率计算，总销售额则增长6%。其中制药业务销售额高达114.69亿瑞士法郎，占集团销售额的77.9%，诊断业务销售额32.53亿瑞士法郎，占22.1%。在上一季度曾经令投资者们失望的重磅眼科药物Vabysmo，第一季度实现销售额显著增长13%，并显示出在美国市场可能出现强劲复苏的迹象;此前，罗氏不得不加大资助力度，以帮助患者们获得该药物。罗氏股价今年以来已下跌近5%。罗氏股价今年以来疲软，本质上是市场在交易三重担忧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1574","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629023400?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","UGA","VXUS","BK1589","159992","DBO","DRLL","GUSH","BK1161","LU0455707207.USD","USE","BK1583","BK1574","IEO","BNO","01530","OIH","03692","01801","DUG","LU2097828805.USD","BK4570","BK1191","09995","LU2242644610.SGD","LU2097828557.USD","DBC","OILT","LU2488822045.USD","OILU","LU2097828631.EUR","USOI","DBE","VDE","LU2097828474.EUR","LU1969619763.USD","BK1593","06978","DIG","BWET","LU2097828714.EUR","HK0000165453.HKD","PXJ","BK4585","ERX","DRIP","IXC","LU2328871848.SGD","USL","OILK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629036430","title":"生物医药板块承压 康方生物(09926)跌超10%、再鼎医药(09688)跌近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629036430","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629036430?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 10:57","pubTimestamp":1776913023,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块承压，截至发稿，康方生物 跌10.45%，再鼎医药跌6.96%，康诺亚-B跌5.25%，荣昌生物跌5.36%，君实生物跌4.66%，诺诚健华跌4.30%，复宏汉霖跌4.46%。消息面上，中信建投证券研究指，本周制药行业表现一般，但恒瑞医药、信达生物、百济神州、海思科、贝达药业等企业的产品管线及对外合作迎来新进展。生物制品板块本周跑赢医药指数，跑输大盘；中药及医药商业板块本周跑输申万医药及大盘。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979735","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","BK4588","BK4139","LU0348784397.USD","BK1583","LU0417516571.SGD","LU2476274720.SGD","XBI","LU2399975544.HKD","LU1794554557.SGD","BK1574","02162","BK4548","09995","BK1515","09969","HK0000320264.USD","LU2778985437.USD","161726","LU0348766576.USD","LU0540923850.HKD","BK4585","BK1161","LU1720050803.USD","ZLAB","LU0561508036.HKD","HK0000320223.HKD","HK0000306685.HKD","09688","HK0000165453.HKD","LU0417516902.SGD","LU2328871848.SGD","LU2476274308.USD","IE00B543WZ88.USD","LU0348783233.USD","BK4526","LU1969619763.USD","LU0348767384.USD","LU1961090484.USD","01877","BK4531","IE00B5MMRT66.SGD","399441","LU0348735423.USD","LU0348825331.USD","BK4581","LU0634319403.HKD","09926","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629003465","title":"康方生物(09926)出现大手卖出11.6万股，成交价$132.0，涉资1.531千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2629003465","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629003465?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 10:55","pubTimestamp":1776912900,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午10:55出现大手卖出，成交量为11.6万，成交价为港币$132.0，涉资1.531千万。至目前为止，股价跌11.52%，今日最高价为$147.0，而最低价为$131.5，总成交量为1.282千万股，总成交金额港币$17.382亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604236232/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604236232/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0417516902.SGD","LU1720050803.USD","LU0540923850.HKD","BK1574","BK1161","LU2488822045.USD","LU0348735423.USD","LU0348766576.USD","09926","LU2476274720.SGD","LU2778985437.USD","LU0348767384.USD","LU0561508036.HKD","LU0417516738.SGD","LU2399975544.HKD","LU0417516571.SGD","LU2476274308.USD","LU0348783233.USD","LU0348827113.USD","LU0348784397.USD","LU0634319403.HKD","LU1961090484.USD","IE00BPRC5H50.USD","LU0348825331.USD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629008808","title":"港股异动 | 亿腾嘉和(06998)涨近4% 于2026年AACR年会公布四特异性抗体EDP001临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629008808","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629008808?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 10:12","pubTimestamp":1776910356,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亿腾嘉和涨近4%，截至发稿，涨3.34%，报3.4港元，成交额513.4万港元。消息面上，4月22日，据亿腾嘉和官微消息，公司宣布自主研发的具有高度创新性的四特异性T细胞衔接器EDP001在2026年美国癌症研究协会年会上公布临床前研究数据。临床前研究显示，EDP001具备强大的体外细胞杀伤能力、显著的体内肿瘤生长抑制作用，以及较低的细胞因子分泌水平。这些结果提示EDP001在B细胞淋巴瘤及B细胞相关自身免疫性疾病中具有良好的临床应用前景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4585","BK1161","BK1222","06998","02276","BK1583","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629315074","title":"和誉-B(02256)：和誉医药于2026年AACR年会展示六项研究进展，聚焦pan-KRAS、四代EGFR及合成致死等创新路线","url":"https://stock-news.laohu8.com/highlight/detail?id=2629315074","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629315074?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 08:05","pubTimestamp":1776902727,"startTime":"0","endTime":"0","summary":"研究结果表明，ABSK211可通过多机制协同显著增强抗肿瘤效果，为后续联合多种治疗策略进入临床开发提供了支持。研究结果支持进一步开发ABK-EGFR-1作为下一代靶向治疗药物，用于 EGFR耐药肿瘤，尤其适用于伴有脑转移的患者。和誉医药在本次2026年AACR年会上集中展示了多个产品管线的最新临床前研究和转化医学研究进展，体现了公司在早期药物发现与开发方面的强大能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","LU2476274720.SGD","LU2488822045.USD","IE00BPRC5H50.USD","BK1574","09939","IE00B543WZ88.USD","BK1161","BK1515","IE00B5MMRT66.SGD","LU2778985437.USD","LU2476274308.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079406","title":"创胜集团医药-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER阳性╱HER2阴性乳腺癌PDX模型中显示出强大的抗肿瘤活性的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079406","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079406?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 07:00","pubTimestamp":1776898849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 公布，于2026年AACR年会上发表强调其自主研发的LIV1抗体偶联药物的临床前数据。对于LIV1表达的前列腺癌PDX模型，ADC-2在给药两剂后显示出有限的肿瘤生长抑制。总体而言，该等数据证明创胜医药的LIV1 ADC-2及ADC-3项目在ER阳性╱Her2 阴性乳腺癌以及前列腺癌的PDX模型中作为单药疗法显示出强大的抗肿瘤活性。该等结果支持进一步研究创胜医药的LIV1 ADC在LIV1阳性实体瘤中的应用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PDX","BK1161","BK4231","06628","ADC","BK1515","09939","BK1574","159938","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629761079","title":"恒瑞医药一季度创新药销售收入超45亿元；甘李药业募投项目延期｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629761079","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629761079?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 07:00","pubTimestamp":1776898807,"startTime":"0","endTime":"0","summary":"｜2026年4月23日星期四｜NO.1各地公开征集违法违规使用医保基金线索4月22日，据国家医保局微信公众号，为深化医保基金管理突出问题整治，充分调动广大人民群众参与医保基金监管的积极性、主动性，全国各地医保部门陆续发布公告，面向全社会公开征集违法违规使用医保基金问题线索，接受群众举报监督，举报线索经查证属实，将按规定给予奖励，最高奖励20万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233714866480.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233714866480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828714.EUR","LU2488822045.USD","600276","BK0188","LU2097828631.EUR","LU0359201885.HKD","06978","603087","LU1969619763.USD","LU2097828474.EUR","LU1997245094.SGD","BK0028","LU2543165471.USD","LU1023057109.AUD","01276","LU1064131003.USD","LU0405327494.USD","LU2097828557.USD","LU1997245177.USD","LU1781817850.SGD","09939","159992","LU1064130708.USD","BK0012","LU0359201612.USD","LU2495084118.USD","LU1820825898.SGD","LU2580892789.USD","LU1997244956.HKD","LU2328871848.SGD","159938","BK0196","BK0239","BK1574","LU2148510915.USD","LU1255011170.USD","BK0183","LU1655091616.SGD","BK1191","BK1515","LU0405327148.USD","LU1580142542.USD","BK0060","LU2289578879.USD","LU1328615791.USD","LU2097828805.USD","LU1146622755.USD","LU2580892862.HKD","LU0359202008.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629160076","title":"加科思-B(01167)4月22日耗资约49.12万港元回购6.27万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629160076","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629160076?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 06:15","pubTimestamp":1776896104,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)公布，2026年4月22日耗资约49.12万港元回购6.27万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629022259","title":"艾伯维斥资14亿美元在北卡罗来纳州建制药园区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629022259","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629022259?lang=zh_cn&edition=fundamental","pubTime":"2026-04-23 03:32","pubTimestamp":1776886320,"startTime":"0","endTime":"0","summary":"2026年4月22日，全球生物制药巨头艾伯维公司宣布了一项重大投资计划，将斥资14亿美元在美国北卡罗来纳州达勒姆市建设一个全新的制药制造园区。这是该公司迄今为止在单一地点进行的最大规模投资。　　根据规划，这座占地185英亩的新园区将成为艾伯维在美国主要的注射药物生产基地，旨在扩大其国内产能，以满足全球市场对关键药物的需求。　　此项投资是艾伯维未来十年在美国投入约1000亿美元用于研发和制造宏伟计划的重要组成部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-23/doc-inhvmmmn5225636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":2,"totalSize":243,"code":"91000000","status":"200"}]}}